Sareum Holdings PLC

Sareum Holdings PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)168.00
  • Today's Change3.50 / 2.13%
  • Shares traded42.18k
  • 1 Year change-62.67%
  • Beta-0.2986
Data delayed at least 20 minutes, as of Aug 11 2022 17:06 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Jun 30 2021202120202019
Net income(1.72)(1.12)(1.68)
Non-Cash items0.010.030.12
Cash taxes paid, supplemental(0.13)(0.23)(0.25)
Cash interest paid, supplemental------
Changes in working capital0.130.280.29
Total cash from operations(1.57)(0.81)(1.26)
Capital expenditures00.00--
Other investing and cash flow items, total(0.04)0.000.00
Total cash from investing(0.04)0.000.00
Financing cash flow items------
Total cash dividends paid------
Issuance (retirement) of stock, net2.491.700.80
Issuance (retirement) of debt, net--00.00
Total cash from financing2.491.700.80
Foreign exchange effects------
Net change in cash0.880.88(0.46)
Net cash-begin balance/reserved for future use1.800.921.38
Net cash-end balance/reserved for future use2.691.800.92
Depreciation, supplemental0.000.000.01
Cash interest paid, supplemental------
Cash taxes paid, supplemental(0.13)(0.23)(0.25)
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.